10:31 AM EDT, 08/15/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) still faces "unanswered questions" over demand for its Elevidys gene therapy, Deutsche Bank said in a note Friday, despite the company avoiding a worst-case financial scenario.

The firm said recent events, including a company restructuring, a voluntary pause in Elevidys shipments at the recommendation of the US Food and Drug Administration, and the subsequent resumption of shipments after the agency's safety review concluded a reported patient death was unrelated to the therapy.

The brief departure and subsequent return of Vinay Prasad, head of the FDA division that oversees gene therapies, was another sign of regulatory turbulence, according to the note.

Due diligence with physicians at large Duchenne muscular dystrophy treatment centers, former and current board members, and administrators of major patient advocacy groups "painted a mixed picture" of Elevidys demand.

Deutsche Bank reiterated its sell rating on Sarepta and raised its price target to $12 from $6.

Price: 20.29, Change: -0.02, Percent Change: -0.08